Furthermore, a recent study revealed that ESRP1 overexpression in paclitaxel-resistant population of triple-negative breast cancer cells increases their sensitivity to paclitaxel by regulating α6 integrin splicing [67]. This evidence concerns the gene ESRP1 and triple-negative breast carcinoma.